Camtech: A Leader in Point‑of‑Care Diagnostics
Camtech develops and commercializes point-of-care tests across healthcare, agriculture, and food safety. We partner with researchers, biotech companies, and industry leaders to turn innovative biomarkers and technologies into rapid, reliable diagnostic solutions. With expertise spanning assay development, product development, and scalable manufacturing, we help accelerate the path from scientific discovery to commercial point-of-care testing.
Clinical Diagnostics
›
- Haemolysis Detection Test
- Infectious Disease Tests
- Tropical Disease Tests
Food Safety ›
- 3-MCPDE & GE Rapid test kit
- Mycotoxin test kits
- BluLine Portable Fecal Detector
- Qualitative Rapid Test Kits
- ELISA Test Kits
Research Tools ›
- Gold Sensors
- Carbon Sensors
Latest News
Singapore
HSA Registers Camtech’s 5‑in‑1 Respiratory Combo Test
Camtech Diagnostics’ COVID‑19/RSV/ADV/Flu A&B 5‑in‑1 Combo Rapid Test Kit has been officially registered by the Singapore Health Sciences Authority (HSA), enabling broad clinical and at‑home use for fast identification of five common respiratory viruses in just 15 minutes. The assay delivers comprehensive detection with strong clinical performance, supporting timely decision‑making for symptomatic individuals.
Visit Camtech Health ›
Oxford, United Kingdom
URICA Haemolysis Test Development Announced
Camtech Diagnostics and the University of Oxford have jointly advanced a novel urinary biomarker into a rapid, non‑invasive 15‑minute test for intravascular haemolysis, tested with patients across the UK, Peru, and Bangladesh. This breakthrough combines Oxford’s discovery with Camtech’s assay engineering and manufacturing expertise to deliver a practical frontline diagnostic.
Visit URICA test website ›
European Vaccine Initiative
DRAIGON: pioneering global initiative using AI to predict antimicrobial resistance from genomic data
Camtech is partnering with an international consortium on an ambitious mission to develop a novel diagnostic tool to tackle antimicrobial resistance (AMR) through the integration of genome sequencing and artificial intelligence (AI) technologies for patients infected with multi-drug resistant pathogens. Camtech will take part in the project by developing a microfluidic device to automate the labour intensive DNA preparation process.
Visit the draigon.eu website ›
